Literature DB >> 26873007

[Recurrent hypoglycemia due to an occult insulinoma].

T G K Breuer1, H L Breuer2, B A Menge1, A Giese1, W Uhl2, W E Schmidt1, A Tannapfel3, D Wild4, M A Nauck1, J J Meier5.   

Abstract

A 64-year-old woman presented with a history of recurrent hypoglycemia. A prolonged fasting test revealed an increased "amended" insulin-glucose ratio. Transabdominal ultrasound (US), computed tomography (CT) scan, and magnetic resonance imaging (MRI) did not show abnormal results. An insulinoma was suspected based on a contrast-enhanced endoscopic US examination as well as a (68)gallium-DOTA-exendin-4 positron-emission tomography (PET)/CT. The diagnosis of an insulinoma was confirmed histologically after surgical removal of the tumor. Hypoglycemia did not occur during the postoperative period. The prolonged fasting test is the gold standard for the diagnosis of an insulinoma. Novel imaging procedures, such as contrast-enhanced endoscopic US or (68)gallium-DOTA-exendin-4 PET/CT are valuable additions to the diagnostic workup.

Entities:  

Keywords:  Endoscopic ultrasonography; Exendin-4; Positron-emission tomography; Prolonged fasting test

Mesh:

Year:  2016        PMID: 26873007     DOI: 10.1007/s00108-016-0020-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  10 in total

Review 1.  Postoperative pancreatic fistula: an international study group (ISGPF) definition.

Authors:  Claudio Bassi; Christos Dervenis; Giovanni Butturini; Abe Fingerhut; Charles Yeo; Jakob Izbicki; John Neoptolemos; Michael Sarr; William Traverso; Marcus Buchler
Journal:  Surgery       Date:  2005-07       Impact factor: 3.982

2.  Well-differentiated pancreatic tumor/carcinoma: insulinoma.

Authors:  Wouter W de Herder; Bruno Niederle; Jean-Yves Scoazec; Stanislas Pauwels; Gunter Kloppel; Massimo Falconi; Dik J Kwekkeboom; Kjel Oberg; Barbro Eriksson; Bertram Wiedenmann; Guido Rindi; Dermot O'Toole; Diego Ferone
Journal:  Neuroendocrinology       Date:  2007-02-20       Impact factor: 4.914

Review 3.  Insulinoma.

Authors:  Kimberly Vanderveen; Clive Grant
Journal:  Cancer Treat Res       Date:  2010

4.  Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.

Authors:  Kwadwo Antwi; Melpomeni Fani; Guillaume Nicolas; Christof Rottenburger; Tobias Heye; Jean Claude Reubi; Beat Gloor; Emanuel Christ; Damian Wild
Journal:  J Nucl Med       Date:  2015-05-21       Impact factor: 10.057

Review 5.  Pancreatic endocrine tumors.

Authors:  Kjell Oberg
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

6.  Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study.

Authors:  F J Service; M M McMahon; P C O'Brien; D J Ballard
Journal:  Mayo Clin Proc       Date:  1991-07       Impact factor: 7.616

7.  Diagnostic accuracy of an "amended" insulin-glucose ratio for the biochemical diagnosis of insulinomas.

Authors:  Michael A Nauck; Juris J Meier
Journal:  Ann Intern Med       Date:  2012-12-04       Impact factor: 25.391

8.  Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline.

Authors:  Philip E Cryer; Lloyd Axelrod; Ashley B Grossman; Simon R Heller; Victor M Montori; Elizabeth R Seaquist; F John Service
Journal:  J Clin Endocrinol Metab       Date:  2008-12-16       Impact factor: 5.958

9.  Endoscopic ultrasonography (EUS) in the localization of insulinoma.

Authors:  Rasoul Sotoudehmanesh; Anooshirvan Hedayat; Nahid Shirazian; Shadi Shahraeeni; Sanaz Ainechi; Fatemeh Zeinali; Shadi Kolahdoozan
Journal:  Endocrine       Date:  2007-06       Impact factor: 3.633

10.  Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.

Authors:  Emanuel Christ; Damian Wild; Susanne Ederer; Martin Béhé; Guillaume Nicolas; Martyn E Caplin; Michael Brändle; Thomas Clerici; Stefan Fischli; Christoph Stettler; Peter J Ell; Jochen Seufert; Beat Gloor; Aurel Perren; Jean Claude Reubi; Flavio Forrer
Journal:  Lancet Diabetes Endocrinol       Date:  2013-07-25       Impact factor: 32.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.